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Summary  
 
The Indian pharmaceutical sector grew spectacularly in a process patent regime, which enabled 
to entrench itself in the global market with generics and cost effective manufacturing processes. 
The legislative environment in India for the pharmaceutical sector underwent changes in 2005 
leading to product patent protection. The sector was ready to embark on a smooth journey to path 
breaking innovation, equipped with enhanced process capabilities as well as expertise gained in 
modular aspects of drug innovation. Is innovation taking place in a manner as would have been 
expected?  
The aim of this paper is to understand how the changes in patent regime have influenced the 
scientific innovation networks, through the lens of national innovation system and open 
innovation. This study examines an important and unexplored facet of open innovation and the 
findings may have important implications for organizations to further their innovation agenda. 
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Purpose of research 
 
Over the past forty years, the Indian pharmaceutical sector has participated in the changes in 
regulatory regime, from a process patent environment in 1970 to a product patent environment in 
2005. The implementation of Trade Related Intellectual Property Rights (TRIPS) agreement and 
the ensuing Patent Amendments Act in 2005, engendered new policy initiatives, increased funds 
for research and development (R&D) and efforts to boost state-industry-academic relationship. 
The question, how changes in the national environment influences formation of innovation 
networks in an Indian setting, remains an under-researched area. This, therefore, forms the 
primary objective. The interplay of various factors influencing interactions taking place between 
the key innovating factors forms the secondary objective. These objectives are pursued through 
the theoretical lens of national innovation system  (Nelson Richard, 1993, Freeman, 1992, 
Lundvall, 1992) and open innovation (Chesbrough, 2003a, Chesbrough, 2003b), which underpin 
the concepts of science-industry interaction and open approaches in R&D.   
 
Theoretical Background 
 
National Innovation System Perspective 
 
The literature on national innovation systems has evolved since the 1980s (Gregersen, 1992, 
Freeman, 1987, Lundvall, 1992, Mowery, 1992, Nelson Richard, 1993) and emphasized the role 
of innovation in influencing the growth and productivity of national output (Baumol, 2002, Tidd 
and Bessant, 2011, Schumpeter, 1934, Nelson and Rosenberg, 1993). This research focuses on 
two main strands of literature in NIS Ð a) selection environment and b) innovation networks - 
linkages formed between industry and science for innovation. 
 
Selection Environment. Two important factors which play a determining role in shaping selection 
environment and influencing firm behaviour are: a) market element  that focuses on commercial 
and profitability considerations b) non-market element which encompasses public agency, 
financing sources, policy issues, political constraints and regulatory issues (Nelson and Winter, 
1977, Dosi, 1982, Utterback and Surez, 1993). The interplay of both these factors has warranted 
intervention from policymakers in the form of financial support, education and training facilities, 
R&D institutions, infrastructure facilities, and regulations  (Gregersen, 1992, Hall, 2002).  
 
Innovation networks.  A considerable body of research illustrates the different roles university, 
public research labs and firms play in the innovation ecosystem and their linkages for basic and 
applied research (Cockburn and Henderson, 1996). The role of public policy has been to 
coxswain linkages and mobilize competencies between public and private research sectors 
(OECD, 2002).  The figure below depicts the mechanisms through which science industry 
interactions take place.  
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Figure 1 - Science Industry Interactions 
 
Source: (OECD, 2002) 
 
Open approaches in pharmaceutical innovation  
  
The open innovation approach (Chesbrough, 2003b) rests on the underlying argument, that the 
traditional in-house R&D structure is losing ground (Chesbrough, 2003b, Chesbrough et al., 
2006) and becoming modularized at each stage of drug discovery and development process 
(Sampath, 2008, London School of Economics and Political Science, 2005). Increasing costs, 
complexity and multidisciplinary nature of pharmaceutical innovation, compounded with drug 
failures, and patent expirations of blockbuster drugs have formed a basis for the emergence of 
innovation networks (Arora and Gambardella, 1990, Cockburn and Henderson, 1996, Hess and 
Rothaermel, 2011, Melese et al., 2009, Powell et al., 1996). A recent proposal of World Health 
Organization (WHO) to reformulate the patent based R&D model of pharmaceutical sector to a 
more open approach, by means of sharing funds, grants to developing countries, milestone based 
payments, and patent pool, signifies the need for more open innovation in this sector (Correa, 
2012). Table 1 summarizes the dimensions of open innovation approach by various authors. 
 
Table 1: Dimensions of open innovation approaches 
!
Dimensions of open innovation approaches Industry/Sector Study 
In-house 
R&D with 
outsourcing 
activities 
Internationalization of R&D 
Outsourcing of R&D 
External commercialization of intellectual property 
Companies with R&D 
Labs 
(Gassmann, 2006, 
Chesbrough, 2003a, 
Chesbrough and 
Crowther, 2006) 
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Pharmaceutical outsourcing to China and India 
Low risk partnering options for multinationals 
Biotech 
Pharmaceuticals 
Fine chemicals 
(Rosebush et al., 
2012, Bhatt, 2007)  
 
 
 
 
 
 
 
 
 
 
 
 
Collaborative 
Innovation 
mode 
Firm-centric network with offshore outposts Across range of R&D 
companies 
(Jelinek et al., 
2012) 
Bidirectional Information exchange 
Transfer of basic knowledge from public funded 
institutions to firms 
Extensive co-authoring between researchers of 
industry and public sector 
Pharmaceutical firms (Henderson and 
Cockburn, 1996) 
Innovation networks between academia and industry 
o One company-one investigator 
o One company-one university 
o One company supports a university consortium 
o One company supports a university institute 
o Industry consortium (pre- or non-competitive) 
o Competition 
o Venture capital investment 
o Fee-for-service 
Biopharmaceutical 
innovation 
(Melese et al., 
2009). 
Industry wide, targeted, collaborative innovation 
efforts 
Across range of R&D 
companies 
(Jelinek et al., 
2012) 
Academic patenting 
Licensing 
Technology transfer office 
Medical technologies and 
drugs 
(Sampat, 2010) 
Open approaches to R&D 
Pooled funds 
Grants to companies in developing countries 
Prizes for milestones and end products 
Patent pools 
 New drugs  
 
(Correa, 2012) 
 
 
 
 
Virtual Labs 
Virtual, ad hoc networks of resources.   Drug R&D (Jelinek et al., 
2012) 
Network position and firm performance 
Alliances for resources learning 
Biotechnology (Koput and Powell, 
2000) 
Public private partnerships for neglected diseases 
Modular approach to R&D 
 
Neglected diseases (London School of 
Economics and 
Political Science, 
2005) 
Open Source Model in drug discovery  New drugs 
 
(rdal and 
R¿ttingen, 2012) 
 
 
Pharmaceutical Innovation System in India 
 
The evolution of the Indian pharmaceutical industry took place in a policy environment, which 
restricted FDI and encouraged process patent regime. This enabled the domestic firms to hone 
their capabilities of reverse engineering, learn and adapt technology, in a protected environment 
(Iyer, 2012, Feinberg and Majumdar, 2001). Post 2005, the change in patent regime caused the 
government to step up measures to support innovation (Department of Science and Technology, 
2013). As noted in the classic works of (Arrow, 1962),  a strong appropriability regime enables 
the ability to profit from innovation and acts as a major incentive for firms to conduct R&D. In 
the Indian pharmaceutical set up too, a change in patent regime coupled with policy measures, 
resulted in R&D investment by established firms (Chowdhary, 2010b, Gehl Sampath, 2006), 
setup of startups and university spin-off for new drug research.  
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Conceptual Framework 
 
The conceptual framework is a congruence of two bodies of literature the national innovation 
system and open innovation and aims to study the open innovation networks formed between 
firms, public research institutes/universities for new drug research. The scope of the study is, 
new drug innovation in the Indian pharmaceutical industry. 
 
 
 
Figure 2: Conceptual Framework 
 
The main research questions are:  
 
RQ 1: How does the patent regime influence formation of innovation networks between 
innovating institutions? 
RQ 2:  What are the different open innovation approaches adopted by different innovating 
entities to undertake new drug research?  
 
Methodological Considerations 
!
The Indian pharmaceutical industry dealing with contemporary issues entails posing of ÔwhatÕ is 
happening and ÔhowÕ or ÔwhyÕ questions and this provides a rationale to pursue case study 
research than other methods (Gummesson, 2007). The research framework leads to qualitative 
case study-based research design and the primary data collection mode is semi-structured 
interviews based on purposive sampling (Bryman, 2011, Creswell, 2009, Mark Easterby Smith, 
2008). Empirical evidence is drawn from 39 semi-structured interviews with senior management 
executives of pharmaceutical companies, academics, public research scientists and experienced 
Inhouse  
research 
Collaborative  
R&D 
Virtual Labs 
RQ1 
Shift in Patent Regime  
Process Patent regime (Pre 2005) to Product Patent regime (Post 2005) 
 Open Innovation 
Approaches 
Open Innovation 
Theory  
(H. W. Chesbrough, 
2003;  
H. W. Chesbrough, 
2006; Gassmann & 
Enkel, 2004, 
Gassmann, 2006, 
Cockburn and 
Henderson 1996, 
Melese et al., 2009, 
Jelinek et al., 2012)  
National 
Innovation System 
Theory  
(Christopher Freeman, 
1987; Gregersen, 1992; 
Lundvall, 1992; David 
C. Mowery, 1992; 
Nelson Richard, 1993)  
RQ2   
 Innovation Networks 
Firms 
Public 
Research 
Labs 
Universities 
Open Innovation Networks in Indian Pharmaceutical Sector 
!
professionals. The cases of universities, public research labs and pharmaceutical companies are 
populated as a collective case study (Stake, 2005) for cross case analysis (Huberman and Miles, 
2005).  
 
Initial findings and discussions 
 
Patent Regime and Innovation Networks   
 
The Patents Act 1970, which abolished the product patent protection (Chowdhary, 2010a)  
enabled firms to reverse engineer drugs that were product patented in other countries (Chittoor et 
al., 2009). The initial success of these companies instilled confidence and they then diversified 
their business into generics, active pharmaceutical ingredients, biogenerics, biotechnology, 
contract manufacturing and research activities for preclinical and clinical research (Chowdhary, 
2010a). Engagements with foreign companies for contract research work enabled India to gain 
expertise in modular stages of drug discovery research (Sampath, 2008). 
 
While the Indian pharmaceutical companies were busy etching out their businesses, state funded 
Indian universities primarily continued as teaching institutes. Throughout this period, research 
activities and patenting at universities remained at ebb. Indian firms followed a closed in-house 
R&D program with minimal interaction with universities or pubic research labs. The disconnect 
between public and private organizations widened over a period of time until the TRIPS patent 
regime resurrected the innovation scene.  
 
TRIPs regime: Plethora of opportunities 
 
The patent regime brought with it other enabling changes such as increased budgetary allocations 
for research, IP awareness programs, and policies to link science with industry and other 
scientific community (Department of Science and Technology, 2013). 
 
Universities: Ostensibly, funding has increased significantly for research grants and capacity 
building. Intellectual property departments have been established as part of the initiative in major 
Indian universities.  
 
ÒWe have been earlier very conservative when it came to dealing with IP but I suppose 
we have understood the need for creating and capturing value through formal intellectual 
propertyÓ- Managing Director, Innovation and Technology Transfer, University 
 
Public research labs: State funded research institutes were the biggest beneficiaries of the 
budgetary allocations in research. The Council for Scientific and Industrial Research (CSIR) 
have initiated an Open Source Drug Discovery (OSDD) research consortium, which has 
leveraged the virtual lab concept to encourage collaboration among Indian researchers (rdal 
and R¿ttingen, 2012) 
 
ÒIts an open source drug discovery platform funded by the government of India. We have 
currently more than 7,500 registered users in the OSDD website which shows that this 
initiative is much more than few individuals and few institutesÓÐ Project Director, OSDD 
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Firms: A host of policy initiatives such as university-corporate R&D spending, lab to industry 
conversion, soft loans, and indigenous innovation has proved beneficial for firms to stimulate 
research and development for new drugs.  
 
ÒIn terms of financial incentives, we have got new grants from the government to help us 
develop novel chemical entities; either we take them during the discovery, pre-clinical 
development or clinical developmentÓ Ð Chief Scientific Officer, Pharmaceutical Firm  
 
Collaborative scene in India 
 
There is a general consensus among the interviewees about the need for forming teams of 
scientists with different expertise for more engaged new drug research. Pharmaceutical 
companies believe that research in universities is useful in the early stages of drug discovery as 
Òthey can work on different strategies and look at different chemical pathways, which companies 
can cherry pick and pursueÓ (Chief Scientific Officer, Pharmaceutical Firm). Although empirical 
research suggests that many collaborative deals have been inked, a notable pharmaceutical expert 
suggested that there is Òmore fluff than wheatÓ (Author and CEO, iDDPartners USA). The figure 
below summarizes the broad range of interactions between industry and science in the innovation 
system. 
 
 
Figure 3: Innovation Networks for New Drug Research in India 
 
Fee for service 
Tie up for Recruitment 
Internship programs/ 
Student projects 
PhD Exchange Programs 
Govt. initiated 
Collaborative Projects 
Scientific Advisory Board 
Member 
Universities 
Basic Research Projects 
Consultancy 
Conferences 
Firms with NCE 
operations (Pre 2005) 
Govt. Initiatives 
Usage of Facilities 
Academic Projects 
Basic Research Projects 
Public Research Labs 
 
Guest Lectures/Training 
 
Open Source 
Drug Discovery 
Firms with NCE 
operations  
(Post 2005) 
Venture Capital funding Virtual R&D Labs 
 
Facilities 
 
Interactions of firms with NCE operations Pre 2005 
Interactions of firms with NCE operations Post 2005 
Interactions of University with Public Research labs 
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The nature of innovation networks formed by firms engaged in NCE research, prior to 2005 are 
primarily of the nature of exchange programs at PhD level, employment of scientists trained in 
public universities, funding short term academic projects, guest lectures, student internships and 
practical training courses offered by the industry to students.  Most of the companies, which 
initiated new drug research before 2005, are expected to engage in such linkages due to longer 
periods of interactions within the innovation system, relative to startups. Other forms of 
interactions by established companies for new drug research includes incorporating distinguished 
scientists as members of scientific advisory board and consultancy projects with scientists.  
 
Paradoxically, companies which, newly started their NCE research operations (post 2005) 
seemed to engage with the scientific community in much more integrated ways such as research 
projects with public research labs and academics, participation in virtual research consortium. 
Newer companies also explore the venture capital funding option, which is somehow non-
existent in India for the risky new drug research business. Startups also make use of the 
instrumentation and testing facilities available in public research labs. Despite some promising 
examples of collaborative research projects of firms with universities and public research labs, 
the emergent picture is that of disconnected and loose interactions between the entities for new 
drug innovation. Table 2 summaries the issues faced by each of the entities in undertaking 
collaborative research. 
 
Table 2: Key emergent themes on reasons for low collaboration 
 
 
1. Low Technological Opportunities 
¥  Technical 
competency 
 
"Our expertise in the area of biological science is very limited..... as far as 
basic medical research is concerned,  if you look at the scale of 1 to 10, I 
would say we will be somewhere around number 1 or 2 as compared to 
countries which already have high ranking" -  Retd. Chief Scientific 
Officer, Public Research Institute 
¥  Not much 
research 
happening 
¥  Low quality of 
publications 
  
¥  Lack of 
motivation  
  
ÒWe have to nurture the excellence and we will have to remove the 
bureaucracy; many people are getting to their comfort zone by not doing 
anything. So this is something, which is very dangerous because in a 
government set up it is very difficult to make a person work. In any 
country but definitely in India it has become more of a norm to enjoy the 
job you are having. So they are not really feeling that they are part of 
building this nation"- Scientist, Public Research Lab B 
 
"There will be people who are interested in drug discovery, but you will 
not find a department of drug research or even a course for MSc in drug 
research in universitiesÓ - Professor, University C  
¥  Concentrate on 
basic research 
  
¥  Lack of 
regulatory and 
GMP knowledge 
  
"I know many scientists in Central Drug Research Institute (CDRI) they 
have good understanding and knowledge but I don't know why they are 
more into basic research than in the drug discovery research" -  Vice 
President, Pharmaceutical Firm!
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¥  Poor infrastructure 
¥  Bureaucracy 
¥  Logistic issues 
"Drug discovery is a huge task..the level of activity and the scale at which 
universities operate abroad is several orders of magnitude different than us" Ð 
Scientist, Public Research Institute B!
 !
"It takes so much time with so many clauses in the contract, so its always easy 
to approach a CRO for a particular serviceÓ- Associate Director, 
Pharmaceutical Firm!
¥  Fluctuating research 
funds  
"Funds are getting squeezed and its now in a very bad shape. É.from 40 crore 
INR (400 million) in the past year we are now at 17 crore INR (170 million) 
this year. This is a major setback to our research, we do not have any extra 
money for researchÓ Ð Professor, University D!
2. Issues related to Intellectual Property!
  
¥  Academia more 
interested to publish 
than patent 
"Biggest issue is intellectual property protection.  Usually academic groups 
would like to publish the results of their endeavors quickly while companies 
tend to protect the intellectual property first with patent filing and then start 
publically disclosing it"-  Chief Scientific Officer, Pharmaceutical Firm!
¥  IP sharing an issue "Companies don't want to share the IP with anybody because there is a 
commercial aspect"- Associate Director, Pharmaceutical Firm!
3. Trust!
¥  Mistrust 
"In that context few have approached but I am being very cautious because in 
earlier times, I have been mislead and fooled also. Therefore, now I am very 
cautious, unless and until its going to be on paper black and white only then 
will there be knowledge transfer"-Professor, University A!
¥  Tech transfer issues 
"University or an organization says that they have a certain technology and 
the company which is collaborating or licensing the technology makes an up 
front payment only to realize that the technology is not working"- Vice 
President, Contract Research Firm!
¥  Ownership issues 
"The issue is the ownership of the technology, the molecules, any kind of 
platform they are developing.  The transparency is not there who is going to 
own that. If the assets are coming from a pharmaceutical company they feel 
that academic is just doing a service. An academic professor says that he is 
not doing just a service. He is helping you to understand what a molecule 
does in the biology field" - Head, External R&D Innovation, MNC!
4. Mindset!
¥  Tendency to work 
in silo 
"Can people really get together and form teams?  That is really difficult in 
India. There are not many successful examples also in the last 15-20 years... É
we do very small level collaborations" - Professor, Public-Private Research 
Institute C!
¥  Do not like to 
share facilities 
"Most researchers don't like to share their facilities. If I buy an instrument for 
my lab, the same instrument is bought by 10 other labs though the institute 
could have bought two instruments and everybody could have used it. ItÕs a 
closed kind of thing" - Professor, Public Research Institute A!
¥  Divide between 
academic and 
industry thinking 
"The major problem is the mindset you know we people in academia are!
 free floating. And therefore we do things the way we like to do. That is the !
academics way of looking at it. You know in industry there are tight timelinesÉ
You ask any academic he doesn't understand what quarterly means. Their 
approach is we are doing it and it will finish when it has to finish "- National 
Research Professor, Padma Shri Award Winner, University B!
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Conclusions 
 
The change in patent regime has attracted wide interest among the pharmaceutical firms, 
universities and public research labs to undertake new drug research. Despite considerable 
efforts by the government, the collaborative efforts are disparate and there is little cohesion in the 
innovation approach. The build up momentum is not sufficient to compensate for the insufficient 
capacity at the level of universities, lack of applied research at universities/public research labs, 
and lack of culture of collaborating between academia/public labs and industry. Given the weight 
of partnerships and the challenges faced by the organizations, there is an urgent need for 
introspection by the policymakers to adopt an innovation approach more suitable to the Indian 
needs. This study is an early attempt to make a contribution to the open innovation and national 
innovation system literature through case study of an emerging economy like India.  
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